MedTrace Logo

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

NCT06566183 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2025-07-03

No results posted yet for this study

Summary

The ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting (CABG):percutaneous coronary intervention (PCI).

Conditions

Interventions

PROCEDURE

Guideline-directed medical therapy (GDMT)

Participants receive guideline-directed medical therapy (GDMT).

PROCEDURE

Coronary artery bypass grafting (CABG)

Participants receive coronary artery bypass grafting (CABG).

PROCEDURE

Percutaneous coronary intervention (PCI).

Participants receive percutaneous coronary intervention (PCI).

Sponsors & Collaborators

Principal Investigators

  • S. Bangalore, MD · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2030-12-31
Completion
2032-12-31

Countries

  • United States
  • Brazil
  • India
  • Mexico
  • Poland
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06566183 on ClinicalTrials.gov